| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00405574 | Prostate Cancer | Drug: ATN-224 | Attenuon|Prostate Cancer Clinical Trials Consortium | Phase 2 | 2006-11-01 | 2008-01-28 |
| NCT02508805 | Vertebrogenic Radiculopathy L5, S1 | Drug: Neuromultivit|Drug: Voltaren|Drug: Sirdalud | Valeant Pharmaceuticals International, Inc.|Valeant Russia, LLC | Phase 3 | 2015-05-01 | 2015-09-27 |
| NCT03072030 | Ebola Virus Disease|Prevention | Biological: GamEvac-Combi (vaccine)|Biological: Placebo | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Military medical Academy named after S. M. Kirov | Phase 4 | 2017-06-01 | 2017-03-01 |
| NCT02388672 | Blood Pressure | Dietary Supplement: decaffeinated coffee|Dietary Supplement: chlorogenic acid|Dietary Supplement: green coffee bean extract supplement|Dietary Supplement: placebo | University Hospital Tuebingen | | 2015-03-01 | 2016-01-25 |
| NCT03063073 | Breast Cancer Female | Drug: Dexmedetomidine Injection [Precedex]|Drug: Bupivacaine | South Egypt Cancer Institute | Phase 3 | 2017-02-25 | 2017-02-23 |
| NCT02819843 | Melanoma|Merkel Cell Carcinoma|Other Solid Tumors | Drug: TALIMOGENE LAHERPAREPVEC (TVEC)|Radiation: Hypofractionated Radiotherapy | Memorial Sloan Kettering Cancer Center|Amgen | Phase 2 | 2016-06-01 | 2017-02-22 |
| NCT02663960 | Critical Illness|Kidney Replacement Disorder|Coagulation; Intravascular | Other: fixed citrate doses protocol|Other: adjusted citrate doses protocol | Peking Union Medical College Hospital | Phase 4 | 2015-08-01 | 2016-01-25 |
| NCT02863211 | Cardiovascular Diseases|Vascular Stiffness | St. Boniface General Hospital Research Centre | | 2015-09-01 | 2017-01-30 |
| NCT00262522 | Human Immunodeficiency Virus Infections | Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs) | Abbott | Phase 3 | 2005-11-01 | 2012-02-03 |
| NCT00175877 | Rheumatoid Arthritis | Biological: Certolizumab Pegol | UCB Pharma | Phase 3 | 2005-06-01 | 2013-03-22 |
| NCT01754480 | Parenchymous Tissue Surgical Bleeding | Biological: Fibrin Sealant Grifols|Device: Surgicel | Instituto Grifols, S.A.|Grifols Biologicals Inc. | Phase 3 | 2013-03-01 | 2016-12-16 |
| NCT01571960 | HIV Infections | Biological: GEO-D03 DNA vaccine|Biological: MVA/HIV62B (MVA62B) vaccine|Biological: Placebo for GEO-D03 DNA|Biological: Placebo for MVA62B: | National Institute of Allergy and Infectious Diseases (NIAID)|GeoVax, Inc. | Phase 1 | 2012-04-01 | 2017-01-23 |
| NCT01509781 | in Situ Breast Cancer|Invasive Breast Cancer | Procedure: Insertion of suction drain(s) following mastectomy|Procedure: Adaptive skin sutures. | National Institute of Oncology, Hungary | Phase 3 | 2011-09-01 | 2015-10-05 |
| NCT00596752 | Peripheral Arterial Occlusive Disease | Drug: Alprostadil|Other: Placebo | UCB BIOSCIENCES GmbH|Aptiv Solutions|UCB Pharma | Phase 4 | 2004-03-01 | 2015-02-26 |
| NCT01964989 | Influenza Virus | Biological: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|Biological: Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV) | Seqirus|Novartis Vaccines | Phase 3 | 2013-11-01 | 2016-10-14 |
| NCT02477839 | Epilepsy With Partial-onset Seizures | Drug: Lacosamide|Other: Placebo | UCB BIOSCIENCES, Inc.|UCB Pharma | Phase 3 | 2015-06-01 | 2017-02-02 |
| NCT02326272 | Psoriasis|Plaque Psoriasis | Biological: Certolizumab Pegol|Other: Placebo | UCB Biopharma S.P.R.L.|Dermira, Inc.|UCB Pharma | Phase 3 | 2014-12-01 | 2017-03-09 |
| NCT01521923 | Rheumatoid Arthritis | Biological: Certolizumab Pegol + Methotrexate (MTX)|Biological: Placebo + Methotrexate (MTX) | UCB Pharma | Phase 3 | 2012-01-01 | 2016-11-10 |
| NCT01519791 | Rheumatoid Arthritis | Biological: Certolizumab Pegol|Other: Placebo|Biological: Methotrexate | UCB Pharma SA|UCB Pharma | Phase 3 | 2012-01-01 | 2016-01-20 |
| NCT02743221 | Metastatic Colorectal Cancer | Drug: Trifluridine/tipiracil hydrochloride (S 95005)|Drug: Capecitabine|Drug: Bevacizumab|Drug: Bevacizumab | Institut de Recherches Internationales Servier|Servier | Phase 2 | 2016-04-01 | 2017-03-16 |
